01 October 2005
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia: Final report of the Polish Adult Leukemia Group (PALGCLL1).
Tadeusz Robak, Jerzy Z Błoński, Marek Kasznicki, Joanna Góra-Tybor, Anna Dmoszyńska, Maria Wojtaszko, Aleksander B Skotnicki, Wiesław Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, Lech Konopka, Bernadetta Ceglarek, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, Kazimierz Sułek, Krzysztof WarzochaMed Sci Monit 2005; 11(10): PI71-79 :: ID: 430316
Abstract
BACKGROUND: We previously published an early report of a randomized, multicentertrial on the efficacy and toxicity of cladribine (2-CdA) + prednisone (P) compared with chlorambucil(Chl) + P in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia.Here we present the final report of this study. MATERIAL/METHODS: Of 229 patients, 126 received 2-CdA+Pand 103 Chl+P. Patients with no response or progression after three courses or who relapsed earlier than12 months after completing one treatment were switched to the other. Patients who relapsed later wereretreated with the same schedule as before. RESULTS: Thirty-three patients were retreated with 2-CdA+Pand 19 with Chl+P. Overall response (and complete response) rates were 35% (6%) and 47% (16%), respectively.In 50 patients initially treated with Chl+P and then with 2-CdA+P, complete response (CR) was achievedin 12 (24%) and overall response (OR) in 32 (64%). In 28 patients originally treated with 2-CdA+P andthen with Chl+P, CR in 1 (3%, p=0.01) and OR in 6 (21%, p=0.003) were obtained. We found no statisticallysignificant difference in overall survival time in patients treated initially with 2-CdA+P and Chl+Paged 60 years (4.63 and 5.27 years, respectively, p=0.45), 60-70 years (3.29 and 3.14 years, p=0.79),and >70 years (1.53 and 1.93 years, p=0.11). CONCLUSIONS: 2-CdA+P is significantly more effective asa second-line treatment and re-treatment than Chl+P. However, we found a trend to longer survival inelderly patients treated with Chl+P.
Keywords: Cladribine - administration & dosage, Chlorambucil - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cyclophosphamide - administration & dosage, Doxorubicin - administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Prednisone - administration & dosage, Survival Analysis, Vincristine - administration & dosage
674 8
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
01 Jun 2023 : Clinical Research
Root Canal Numbers and Configurations in 1080 Permanent Canine Teeth in 270 Saudi Subjects Using Cone-Beam ...Med Sci Monit In Press; DOI: 10.12659/MSM.940472
01 Jun 2023 : Clinical Research
Internal Orifice Alloy Closure: A New Procedure for Treatment of Perianal Fistulizing Crohn’s DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.940873
01 Jun 2023 : Clinical Research
Effectiveness of Needle Aspiration versus Surgical Excision for Symptomatic Synovial Cysts of the Hip: A Si...Med Sci Monit In Press; DOI: 10.12659/MSM.940187
01 Jun 2023 : Clinical Research
Influence of Insulin Resistance on Diabetes NephropathyMed Sci Monit In Press; DOI: 10.12659/MSM.939482
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952